Overview

Chronic kidney disease (CKD) is a worldwide public health problem with increasing prevalence. It is associated with several abnormalities in mineral metabolism, such as hypocalcemia and hyperphosphatemia, and abnormalities in vitamin D (Reddy et al., 2014).

Disorders of bone and mineral metabolism are independently related to mortality and morbidity associated with cardiovascular disease and fractures in patients on hemodialysis (HD) or peritoneal dialysis (PD) (Abe, Okada, & Soma, 2013).

The healthy kidney plays the following roles:
• Regulates body fluid volume.
• Regulates electrolyte balance.
• Regulates acid-base balance.
• Removes metabolic waste.
• Regulates blood pressure.
• Excretes drugs and toxins.
• Regulates vitamin D metabolism.
• Regulates the production of erythropoietin.

In normal renal function, the kidneys play an active role in regulating the excretion of waste products and maintaining a delicate balance of minerals in our bodies, while also secreting hormones that impact other body systems.

Disease Manifestation and Possible Symptoms

Clinical Progression of Mineral and Bone Disorder (MBD) in CKD
• Phosphorus excretion diminishes, leading to an increase in serum phosphorus.
• Calcium is not reabsorbed, leading to decreased serum calcium.
• Vitamin D is not activated, leading to hypertrophy and hyperplasia of the parathyroid glands with increased secretion of parathyroid hormone (PTH).
• Both decreased serum calcium levels and increased serum phosphorus levels stimulate excessive secretion of PTH.

An elevated PTH increases both the number and activity of osteoclasts (cells that break down bone). As osteoclasts break down bone, calcium and phosphorus are released into the serum, causing an elevation in phosphorus levels. This leads to demineralized (weakened) bones, which are subject to fractures; falls; and calcification of the heart, vasculature, and soft tissues.

The following disease process occurs as renal function decreases to a point at which the GFR is less than 60 mL/min/1.73m²:
• Decreased urinary phosphorous excretion.
• Decreased vitamin 1,25 D levels due to the kidney’s inability to convert 25 D into 1,25 D, which is the biologically active form.
• Increased PTH secretion as a response to stimulate calcium absorption in the intestines.
• Decreased calcium excretion.

As CKD progresses into Stages 3 and 4, the worsening condition and exacerbation of the above four processes induces serum changes:
• Phosphorus increases.
• PTH increases.
• Calcium imbalance (decreases) due to decreases in vitamin 1,25 D.

This condition may be present and undetected for a long period of time prior to the initiation of renal replacement therapy. If left uncontrolled, clinical evidence has demonstrated an increase in mortality in patients with CKD (Blaine, Chonchol, & Levi, 2015).

The clinical manifestations may include (Greco & Mahon, 2015):
• Exacerbated hyperphosphatemia.
• Secondary hyperparathyroidism (results from retained phosphorus, low levels of vitamin D, and a reduction in serum calcium).
• Risk for calcium overload.
• Itching (due to increased phosphorous or PTH levels).
• Reddened eyes (due to capillary deposition of minerals).
• Bone pain and/or risk for fractures.

Diagnostic Testing

For patients on HD or PD, the following should be maintained at the designated level (KDOQI, 2017).

CKD Stage 5, Patients on Dialysis
• Serum phosphorus (PO₄): 3.5 to 5.5 mg/dL.
• Serum calcium (Ca): 8.4 to 9.5 mg/dL.
• Calcium/phosphorus (CaPO₄) Product: less than 55 mg²/dL².
• PTH: 150 to 300 pg/mL.
In 2009, global recommendations were published by the Kidney Disease: Improving Global Outcomes Group (KDIGO). The following clinical practice guidelines were recommended based on clinical evidence review (London, Coyne, Hruska, Malluche, & Martin, 2010).

Stage 3 (GFR 30 to 59 mL/min/1.73m²)
• PTH: Greater than the upper limit of normal for the assay used.
• Phosphorous: Within normal limit.
• Calcium: Within normal limit.

Stage 4/5 (GFR 15 to 29 mL/min/1.73m²)
• PTH: Greater than the upper limit of normal for the assay used.
• Phosphorous: Maintain normal.
• Calcium: Maintain normal.

Stage 5D (or on Replacement Therapy [RRT])
• PTH: 2 to 9 times the upper limit of normal for the assay used.
• Phosphorous: Treat toward normal.
• Calcium: Maintain normal.

Other Laboratory Tests that May Be Useful for All Stages
• Alkaline phosphatase: 20 to 140 international units/L.
• CO₂: Greater than 22 mEq/L.
• Aluminum levels: Less than 20 mcg/L.
• Vitamin D levels (rarely measured).

Other Diagnostic Testing that May Be Useful
• Bone X-rays for suspected fractures.
• Bone biopsy from the iliac crest.
• Dual imagery X-ray absorptiometry (DXA) to visualize bone lesions.
• Radiographs to detect possible calcifications.
• Electrocardiogram and echocardiogram.

Complications of Mineral Imbalance

Vascular Complications
• Cardiovascular problems resulting in arteriosclerosis, vascular calcification, valvular calcification, and cardiomyopathy.
• Progressing cardiovascular disease may, in turn, lead to cardiovascular problems, such as myocardial infarction, peripheral vascular disease (which presents as calciphylaxis and ulcers in the torso and extremities), and cerebrovascular disease in the form of transient ischemic attacks and cerebrovascular accidents.

Osteodystrophy (Bone Disease) Complications
• Determined by bone biopsy and estimated with monitoring of serum levels.
• High turnover bone diseases:
  ○ Mixed uremic osteodystrophy with varying degrees of mineralization defects and hyperparathyroid changes.
  ○ Osteitis fibrosa is an abnormal bone reabsorption, formation, and marrow fibrosis.
• Low turnover bone diseases:
  ○ Adynamic bone disease suppresses bone formation secondary to hypercalcemia and/or over suppression of PTH.
  ○ Osteomalacia produces large amounts of unmineralized bone, and it may be aluminum- or nonaluminum-related. Osteomalacia has decreased substantially because aluminum binder use has diminished.

Interventions

Interventions to prevent and treat disorders of bone/mineral metabolism include diet, medications, and dialysis. The patient may require surgical intervention if these interventions are not successful.

Diet
Due to a high need for protein consumption, it is virtually impossible to eat a phosphorus-free diet; therefore, phosphorus is restricted, and phosphate binders must be used. Patients should also be instructed to check food labels for potassium, calcium, or phosphorus, which may impact their overall health.

Isakova and colleagues (2017) suggests the following guidelines for daily mineral intake:
• Phosphorus: 800 to 1,000 mg/day.
• Calcium: 1,000 to 1,200 mg/day from all sources (including phosphate binders).

High-phosphorus foods that should be restricted include (Ignatavicius & Workman, 2015; National Institute of Diabetes and Digestive and Kidney Diseases [NIDDK], 2017):
• Dairy products.
• Dark cola.
• Dried beans.
• Whole grains.
• Nuts.
• Baked goods made from a mix.
• Chocolate.
• Foods containing phosphorus additives.
• Processed meats.
Medications

**Phosphate Binders**

Phosphate binders work by binding phosphorus in the digestive system, beginning in the small intestine and eliminated in the stool. It is imperative that binders be administered with food or as per the package insert. Phosphate binders should not be administered with any other medications. Adherence to prescribed regimens is crucial.

Phosphate binders are a commonly prescribed class of drug for patients with renal disease and account for up to 50% of the daily pill burden in patients with CKD. The frequent adverse drug effects (particularly gastrointestinal intolerance) contribute to poor medication adherence. Therefore, patients should be screened for any underlying GI pathology prior to administration of any phosphate binder (Chan et al., 2017).

According to Isakova and colleagues (2017), the following recommendations are stated in the KDOQI and KDIGO guidelines regarding the discontinuation of calcium-based binders in patients with CKD in the presence of:
- Serum calcium greater than 10.2 mg/dL² (KDOQI).
- PTH less than 150 pg/mL² (KDOQI).
- Signs of calcification on radiographs or other diagnostic reports (KDIGO).

**Calcium-Based Binders**

Calcium carbonate (Tums®, Tums® EX), calcium acetate (Phoslo®), and calcium citrate (Citracal®).

**Non-Calcium, Non-Metal-Based Binders**

Sevelamer carbonate (Renvela®) and sevelamer hydrochloride (Renagel®) (Genzyme Corporation, 2007).

**Metal-Based Binders**

Lanthanum carbonate (Fosrenol®) and aluminum (Aluca®p®, Alternagel®, and Basogel®).
- Due to concerns of potential neurological toxicity, it is recommended to avoid or restrict the use of aluminum binders and to advocate for the use of newer binders (Mudge et al., 2011).

**Magnesium-Based Binders**

- MagneBInd®:
  - Requires monitoring of magnesium levels and contains calcium as well (National Kidney Foundation [NKF], 2017a).

**Vitamin D Analogs**

Vitamin D analogs are used to suppress parathyroid production and secretion and to treat hypocalcemia.
- Calcijex® (calcitriol injection):
  - Reduction of PTH has been shown to result in an improvement in renal osteodystrophy (Abbott Laboratories, 2017).
- Rocaltrol® (calcitriol capsules and oral solution):
  - Pre-dialysis patients: Rocaltrol is indicated in the management of secondary hyperparathyroidism and resultant metabolic bone disease in patients with moderate to severe chronic renal failure (CCr 15 to 55 mL/min) mL/m² not yet on dialysis for hyperparathyroidism.
  - Patients on dialysis: Rocaltrol is indicated in the management of hypocalcemia and the resultant metabolic bone disease in patients undergoing chronic renal dialysis.
  - Patients with hypoparathyroidism: Rocaltrol is also indicated in the management of hypocalcemia and its clinical manifestations in patients with postsurgical hyperparathyroidism, idiopathic hyperparathyroidism, and pseudohypoparathyroidism (Validus Pharmaceuticals, 2009).
- Hectorol® (doxercalciferol injection):
  - Hectorol is indicated for the treatment of secondary hyperparathyroidism in patients with CKD on dialysis (Sanofi, 2015).
- Hectorol® (doxercalciferol capsules):
  - Patients on dialysis: Hectorol is indicated for the treatment of secondary hyperparathyroidism in patients with CKD on dialysis.
  - Pre-dialysis patients: Hectorol is indicated for the treatment of secondary hyperparathyroidism in patients with CKD Stage 3 or Stage 4 (Sanofi, 2015b).
- Zemplar® (paricalcitol injection):
  - Zemplar is indicated for the prevention and treatment of secondary hyperparathyroidism associated with CKD Stage 5 (AbbVie Inc., 2016a, 2016b).
- Zemplar® (paricalcitol capsules):
  - Pre-dialysis patients: Zemplar is indicated for the prevention and treatment of secondary hyperparathyroidism associated with CKD Stages 3 and 4 (AbbVie Inc., 2016a, 2016b).
**Calcimimetic Agents (Cinacalcet [Sensipar®])**

**Dialysis (Hemodialysis and Peritoneal Dialysis)**
Dialysate is phosphorus-free to remove the maximum amount of phosphorus. If phosphorus remains elevated, longer or more frequent dialysis may be recommended. The recommended dialysate calcium concentration is 2.5 mg/dL with tailoring to individual patients as needed (NKF, 2017).

**Parathyroidectomy**
Recommended in patients with severe hyperparathyroidism (iPTH persistently greater than 800 pg/mL) with hypercalcemia and hyperphosphatemia, and non-responsive to medical therapy.

**Implications for Nephrology Nursing**
The registered nurse needs to assess, educate (importance of diet and compliance of medications), and monitor laboratory values to prevent the progression of metabolic bone disease. The advanced practice registered nurse needs to assess and intervene as follows (Easom, 2015).

**Assessment**
- Monitor and interpret laboratory results and diagnostic studies and adjust medications as needed.
- Monitor the patient’s ability and response to the treatment plan (i.e., dietary modifications, taking phosphate binders, taking calcium and vitamin D supplements).
- Monitor any development of bone disorders (i.e., calcifications and bone fractures).

**Intervention**
- Treat disorders of CKD-MBD following evidence-based research and guidelines.
- Order additional laboratory and diagnostic studies as appropriate (i.e., X-ray, bone scan, echocardiogram).
- Adjust diet and medication regimen as indicated based on biochemical parameters and patient response to therapy explaining the importance of the modifications to the patient.
- Refer patients with severe CKD-MBD for bone biopsy and additional bone treatment when warranted (i.e., unexplained fractures, unexplained bone pain, unexplained hypophosphatemia, and possible aluminum toxicity).

**References**


**Additional Reading**


---

**ANNA Mission Statement**

ANNA improves members’ lives through education, advocacy, networking, and science.

**Additional Information:**

American Nephrology Nurses Association
East Holly Avenue/Box 56
Pitman, NJ 08071-0056
(856) 256-2320
1 (888) 600-2662

Copyright© 2018
American Nephrology Nurses Association
Pitman, NJ

This fact sheet may be photocopied for education purposes.